Category: Featured Story

The unprecedented results for mesothelioma and melanoma patients being treated with Keytruda (pembrolizumab) have kept the drug in the spotlight over the last year. The benefits of the drug are continuing to impress as the U.S. Food and Drug Administration announced last month that Keytruda is now approved for first-line treatment in melanoma patients. FDA …

Boehringer Ingelheim announced last month that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its investigational cancer drug BI 1482694 for the treatment of non-small cell lung cancer (NSCLC). According to Boehringer Ingelheim, the maker of 1482694, the drug is targeted to NSCLC patients whose tumors have epidermal growth factor (EGFR) …

The protein p53 is one of the body’s most critical defenses in preventing the production of tumors, and if rendered defective, it could lead to uncontrolled tumor growth and metastasis in mesothelioma and other cancers. As a result, p53 protein has been gaining relevance among researchers as the key to killing cancer cells. Now, researchers …